Skip to content
APDN Announces Receipt of Largest Single Purchase Order for LinearDNA™ To-Date
October 10, 2022
Read More email
LinearDNA™ Platform Development Milestone: First Successful Administration of LinearDNA In Vivo via Lipid Nanoparticles (LNP)
August 10, 2022
Read More email
APDN Announces Linear DNA Orders from New Contract Research Customers for Use in RNA Vaccine and Adeno-Associated Virus Applications
November 2, 2020
Read More email
APDN Secures Top-20 Pharmaceutical Manufacturer as Drug Development Customer
March 20, 2020
Read More email
For Applied DNA, New Blood — And A Shot In The Arm
August 14, 2019
Read More email
Medicare Coverage of CAR T-Cell Therapy Holds Positive Implications for LineaRx
August 12, 2019
Read More email
LineaRx Acquires Cancer Cell Assets and Intellectual Property of Vitatex
August 9, 2019
Read More email
LineaRx Acquires Assets and Intellectual Property of Vitatex
August 8, 2019
Read More email
LineaRx Receives Multiple Orders for Linear DNA for Use in Therapeutic Development
July 1, 2019
Read More email
LineaRx to Support Therapy Development for Neurodegenerative Diseases
June 26, 2019
Read More email
LineaRx Anticipates Expansion in Diagnostics Market
May 21, 2019
Read More email
LineaRx Achieves Higher Expression and Survival Rates in Human T Cells
April 29, 2019
Read More email
Linear DNA Crosses the Line between Tags and Therapeutics
April 9, 2019
Read More email
LineaRx Achieves Anti-CD19 Expression in Human CAR T Cells via Plasmid-Free Platform
April 8, 2019
Read More email
LineaRx Provides Cost and Quality Advantages to Technogenetics
November 7, 2018
Read More email
LineaRx Licenses CAR T Drug Candidate, Initiates Pre-Clinical Development of Non-viral, Plasmid-free CAR T Manufacturing Platform
October 16, 2018
Read More email
LineaRx Secures New RNA Therapeutics Customers for Contract Research Services
October 1, 2018
Read More email
LineaRx to Collaborate with Italian Companies Takis and Evvivax on Cancer Vaccines
September 20, 2018
Read More email
LineaRx Signs Joint Development Agreement with Takis and Evvivax to Develop Linear-DNA Based Anti-Cancer Vaccines
September 20, 2018
Read More email
APDN Forms Subsidiary, LineaRx, to Develop DNA for Biotherapeutics
September 18, 2018
Read More email
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. Ok 
